Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul 21;7(1):247.
doi: 10.1038/s41392-022-01115-7.

Olfactory receptor 2 activation in macrophages: novel mediator of atherosclerosis progression

Zuowen He  1   2 , Dao Wen Wang  3   4
Affiliations
Comment

Olfactory receptor 2 activation in macrophages: novel mediator of atherosclerosis progression

Zuowen He et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. Dao Wen Wang is the editorial board member of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling.

Figures

Fig. 1
Fig. 1
Schematic showing mechanisms of OLFR2 ligation-mediated signaling promoting atherosclerosis. Endogenous atherogenic ligands activate TLR4 and subsequently initiate the priming signal of the NLRP3 inflammasome. Octanal derived from oxLDL activates the OLFR2 and the downstream NLRP3 inflammasome activation, which triggers inflammatory cytokine interleukin release, leading to the progression of atherosclerosis. OLFR2 olfactory receptor 2, TLR4 Toll-like receptor 4, NLRP3 NLR family pyrin domain-containing 3, oxLDL oxidized low-density lipoprotein, IL-1β interleukin-1β, IL-1α interleukin-1α. This figure was designed using smart.servier.com
See this image and copyright information in PMC

Comment on

  • Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production.
    Orecchioni M, Kobiyama K, Winkels H, Ghosheh Y, McArdle S, Mikulski Z, Kiosses WB, Fan Z, Wen L, Jung Y, Roy P, Ali AJ, Miyamoto Y, Mangan M, Makings J, Wang Z, Denn A, Vallejo J, Owens M, Durant CP, Braumann S, Mader N, Li L, Matsunami H, Eckmann L, Latz E, Wang Z, Hazen SL, Ley K. Orecchioni M, et al. Science. 2022 Jan 14;375(6577):214-221. doi: 10.1126/science.abg3067. Epub 2022 Jan 13. Science. 2022. PMID: 35025664 Free PMC article.

References

    1. Orecchioni M, et al. Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production. Science. 2022;375:214–221. doi: 10.1126/science.abg3067. - DOI - PMC - PubMed
    1. Cholesterol Treatment Trialists, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5. - DOI - PMC - PubMed
    1. Parmentier M, et al. Expression of members of the putative olfactory receptor gene family in mammalian germ cells. Nature. 1992;355:453–455. doi: 10.1038/355453a0. - DOI - PubMed
    1. Massberg D, Hatt H. Human olfactory receptors: novel cellular functions outside of the nose. Physiol. Rev. 2018;98:1739–1763. doi: 10.1152/physrev.00013.2017. - DOI - PubMed
    1. McArdle S, et al. Migratory and dancing macrophage subsets in atherosclerotic lesions. Circulation Res. 2019;125:1038–1051. doi: 10.1161/CIRCRESAHA.119.315175. - DOI - PMC - PubMed

Publication types

Substances